US2022356148A1PendingUtilityA1
Antiviral compounds
Est. expirySep 13, 2036(~10.2 yrs left)· nominal 20-yr term from priority
Inventors:Wolfgang FischlMark WhittakerChristopher John YarnoldJean-Francois PonsMark Anthony KerryPatricia AmouzeghInaki MoraoPeter Neville IngramEwa Iwona Chudyk
C07C 311/13C07D 307/14C07D 205/04C07D 211/26C07C 2601/04C07C 2601/08C07C 271/24C07D 261/18C07D 233/64C07D 403/12C07C 311/29C07C 237/22C07C 2601/14C07C 311/03C07D 405/06A61P 31/14C07D 417/12C07D 207/26C07D 215/14C07D 241/12C07C 235/74C07C 311/19Y02A50/30C07D 403/06C07C 2601/02C07C 311/06C07D 207/27C07D 309/14C07D 401/12C07D 309/04C07C 311/10
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to novel compounds of general Formula II:wherein the groups X, and R1 to R4 have the meanings given in the description, to a process for preparing these compounds and to their use for treating, preventing or ameliorating viral infections and diseases which are associated with PLA2G16.
Claims
exact text as granted — not AI-modified1 . A compound of general Formula II,
wherein
X denotes —(CH 2 ) n —N—;
R 1 denotes H, —C(O)R a ,—(CH 2 ) n C(O)OR a , or a group, optionally substituted by one or more, identical or different R a and/or R b , selected independently from one another among C 1-8 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-10 aryl, 3-8 membered heterocycloalkyl, and 5-12 membered heteroaryl;
R 1′ denotes H or C 1-4 alkyl;
or R 1 and R 1′ together with the adjacent nitrogen atom form a 4- to 10-membered heterocyclic group, which optionally may be substituted by one or more, identical or different R a and/or R b ;
R 2 denotes H, —C(O)R a , or a group, optionally substituted by one or more, identical or different R a and/or R b , selected independently from one another among C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
R 2′ denotes H or C 1-6 alkyl;
R 4 denotes H, —C(O)R a , or a group, optionally substituted by one or more, identical or different R a and/or R b , selected independently from one another among C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-10 aryl, 3-8 membered heterocycloalkyl, and 5-12 membered heteroaryl;
each R a independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different R b and/or R c , selected from among C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each R b is a suitable substituent and is selected in each case independently of one another from among ═O, —OR c , C 1-3 haloalkyloxy, —OCF 3 , ═S, —SR c , ═NR c , ═NOR c , ═NNR c R c , ═NN(R g )C(O)NR c R c , —NR c R c , —ONR c R c , —N(OR c )R c , —N(R g )NR c R c , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R c , —S(O)OR c , —S(O) 2 R c , —S(O) 2 OR c , —S(O)NR c R c , —S(O) 2 NR c R c , —OS(O)R c , —OS(O) 2 R c , —OS(O) 2 OR c , —OS(O)NR c R c , —OS(O) 2 NR c R c , —C(O)R c , —C(O)OR c , —C(O)SR c , —C(O)NR c R c , —C(O)N(R g )NR c R c , —C(O)N(R g )OR c , —C(NR g )NR c R c , —C(NOH)R c , —C(NOH)NR c R c , —OC(O)R c , —OC(O)OR c , —OC(O)SR c , —OC(O)NR c R c , —OC(NR g )NR c R c , —SC(O)R c , —SC(O)OR c , —SC(O)NR c R c , —SC(NR g )NR c R c , —N(R g )C(O)R c , —N[C(O)R c ] 2 , —N(OR g )C(O)R c , —N(R g )C(NR g )R c , —N(R g )N(R g )C(O)R c , —N[C(O)R c ]NR c R c , —N(R g )C(S)R c , —N(R g )S(O)R c , —N(R g )S(O)OR c , —N(R g )S(O) 2 R c , —N[S(O) 2 R c ] 2 , —N(R g )S(O) 2 OR c , —N(R g )S(O) 2 NR c R c , —N(R g )[S(O) 2 ] 2 R c , —N(R g )C(O)OR c , —N(R g )C(O)SR c , —N(R g )C(O)NR c R c , —N(R g )C(O)NR g NR c R c , —N(R g )N(R g )C(O)NR c R c , —N(R g )C(S)NR c R c , —[N(R g )C(O)] 2 R c , —N(R g )[C(O)] 2 R c , —N{[C(O)] 2 R c } 2 , —N(R g )[C(O)] 2 OR c , —N(R g )[C(O)] 2 NR c R c , —N{[C(O)] 2 OR c } 2 , —N{[C(O)] 2 NR c R c } 2 , —[N(R g )C(O)] 2 OR c , —N(R g )C(NR g )OR c , —N(R g )C(NOH)R c , —N(R g )C(NR g )SR c and —N(R g )C(NR g )NR c R c ;
each R c independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different R d and/or R e , selected from among
C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 4-16 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each R d denotes a suitable substituent and is selected in each case independently of one another from among ═O, —OR e , C 1-3 haloalkyloxy, —OCF 3 , ═S, —SR e , ═NR e , ═NOR e , ═NNR e R e , ═NN(R g )C(O)NR e R e , —NR e R e , —ONR e R e , —N(OR e )R e , —N(R g )NR e R e , halogen, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R e , —S(O)OR e , —S(O) 2 R e , —S(O) 2 OR e , —S(O)NR e R e , —S(O) 2 NR e R e , —OS(O)R e , —OS(O) 2 R e , —OS(O) 2 OR e , —OS(O)NR e R e , —OS(O) 2 NR e R e , —C(O)R e , —C(O)OR e , —C(O)SR e , —C(O)NR e R e , —C(O)N(R g )NR e R e , —C(O)N(R g )OR e , —C(NR g )NR e R e , —C(NOH)R e , —C(NOH)NR e R e , —OC(O)R e , —OC(O)OR e , —OC(O)SR e , —OC(O)NR e R e , —OC(NR g )NR e R e , —SC(O)R e , —SC(O)OR e , —SC(O)NR e R e , —SC(NR g )NR e R e , —N(R g )C(O)R e , —N [C(O)R e ] 2 , —N(OR g )C(O)R e , —N(R g )C(NR g )R e , —N(R g )N(R g )C(O)R e , —N[C(O)R e ]NR e R e , —N(R g )C(S)R e , —N(R g )S(O)R e , —N(R g )S(O)OR e , —N(R g )S(O) 2 R e , —N[S(O) 2 R e ] 2 , —N(R g )S(O) 2 OR e , —N(R g )S(O) 2 NR e R e , —N(R g ) [S(O) 2 ] 2 R e , —N(R g )C(O)OR e , —N(R g )C(O)SR e , —N(R g )C(O)NR e R e , —N(R g )C(O)NR g NR e R e , —N(R g )N(R g )C(O)NR e R e , —N(R g )C(S)NR e R e , —[N(R g )C(O)] 2 R e , —N(R g )[C(O)] 2 R e , —N{[C(O)] 2 R e } 2 , —N(R g )[C(O)] 2 OR e , —N(R g )[C(O)] 2 NR e R e , —N{[C(O)] 2 OR e } 2 , —N{[C(O)] 2 NR e R e } 2 , —[N(R g )C(O)] 2 OR e , —N(R g )C(NR g )OR e , —N(R g )C(NOH)R e , —N(R g )C(NR g )SR e and —N(R g )C(NR g )NR e R e ;
each R e independently of one another denotes hydrogen or a group selected from among C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 6-10 aryl, 3-8 membered heterocycloalkyl, and 5-12 membered heteroaryl;
each R g independently of one another denotes hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 6-10 aryl, 3-8 membered heterocycloalkyl, or 5-12 membered heteroaryl;
n denotes 0, 1, 2 or 3;
optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, hydrates, isotopes, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.
2 . The compound according to claim 1 , wherein X is N.
3 . The compound according to claim 1 , wherein R 4 is selected from optionally substituted C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 3-8 membered heterocycloalkyl, and 5-6 membered heteroaryl.
4 . The compound according to claim 1 , wherein R 1′ is H.
5 . The compound according to claim 1 , R 1 is optionally substituted C 1-6 alkyl or C 3-6 cycloalkyl.
6 . The compound according to claim 1 , wherein R 2′ is H.
7 . The compound according to claim 1 , wherein R 2 is optionally substituted C 1-6 alkyl.
8 . The compound according to claim 1 , wherein the compound is selected from group consisting of:
9 . A method of treating or preventing infectious diseases, cancer, and obesity, comprising the step of administering the compound of claim 1 to a subject in need thereof.
10 . The method of claim 9 , wherein the infectious disease is a viral infection.
11 . The method of claim 10 , wherein the viral infection is a picornavirus infection.
12 . A pharmaceutical preparations containing as a pharmacologically active substance one or more compounds according to claim 1 in combination with one or more pharmacologically acceptable excipients and/or carriers.
13 . The pharmaceutical preparation of claim 12 , comprising at least one further pharmacologically active substanceCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.